MedTrace Logo

The Montefiore Metoclopramide Study

NCT00475306 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 289

Last updated 2012-12-31

Study results available
· View outcomes & findings →

Summary

Metoclopramide is a dopamine antagonist frequently used for the treatment of nausea, vomiting, and migraine headaches in Emergency Departments. However, little research has focused on the optimal dose of metoclopramide for treatment of nausea in the emergency department. We propose a randomized, double-blind, placebo controlled trial to investigate the optimal dose of metoclopramide for treatment of nausea.

Conditions

  • Nausea
  • Extrapyramidal Symptoms

Interventions

DRUG

metoclopramide 10 mg

an anti-emetic medication

DRUG

Diphenhydramine 25 mg

used for prophylaxis against akathisia

DRUG

Placebo

placebo

DRUG

Metoclopramide 20 mg

Metoclopramide 20 mg

Sponsors & Collaborators

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Benjamin W Friedman, MD · Montefiore Medical Center

  • Brooke Bender, MD · Albert Einstein College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00475306 on ClinicalTrials.gov